ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Austin, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near Austin, TX, USA:

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...

Active, not recruiting
Non Small Cell Lung Cancer
Drug: NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
Drug: NAI + Nivolumab + Ipilimumab

Phase 3

ImmunityBio
ImmunityBio

Austin, Texas, United States and 30 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Austin, Texas, United States and 230 other locations

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who ...

Enrolling
Non-Small Cell Lung Cancer
Drug: Zelenectide pevedotin (BT8009)

Phase 2

BicycleTx

Austin, Texas, United States and 12 other locations

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells...

Enrolling
Non-Squamous Non-Small Cell Lung Cancer
Drug: Osimertinib (Osi)
Drug: Telisotuzumab Adizutecan

Phase 2, Phase 3

AbbVie
AbbVie

Austin, Texas, United States and 36 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Round Rock, Texas, United States and 294 other locations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Phase 3

AbbVie
AbbVie

Austin, Texas, United States and 314 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC)....

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Austin, Texas, United States and 30 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Austin, Texas, United States and 347 other locations

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small...

Enrolling
Non Small Cell Lung Cancer
Drug: WSD0922-FU Tablets, Dose level A
Drug: WSD0922-FU Tablets, Dose level B

Phase 2

Wayshine Biopharm, Inc.

Austin, Texas, United States and 17 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Ca...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Austin, Texas, United States and 207 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems